EQNasdaqPharmaceutical PreparationsFiscal year ends December 31
Equillium, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.24+0.05 (+4.20%)
Close on Oct 19, 2026
- Market cap
- $138.64M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -53.4% | -94.0% | |
| Return on assets | – | -42.3% | -77.9% | |
| Current ratio | 12.57 | 11.76 | 10.58 | |
| Debt to equity | – | 0.14 | – | |
| Net debt to EBITDA | – | 0.48× | – | |
| Interest coverage | – | -26.9× | – | |
| Capex to revenue | – | – | – | |
| Diluted shares | – | 20M | 57M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Equillium generated $104.37M from operations and spent $779.00K on capital expenditure, dividends and share buybacks. 67% of that went back into the business.
Generated
$104.37M
Used
$779.00K
Capital expenditure$519.00K67%Dividends$00%Share buybacks$260.00K33%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-19.6%
×Asset turnover1.08×
×Equity multiplier1.83×
=Return on equity, FY2024-38.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -19.6% | 1.08× | 1.83× | -38.8% |
| FY2023 | -37.0% | 0.56× | 2.37× | -48.9% |
| FY2022 | -396.1% | 0.19× | 1.66× | -126.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$22.40M
- Cash generatingOperating cash flow above zero-$22.75M
- Return on assets improvedROA up on the prior year-16.0% → -87.5%
- Earnings backed by cashOperating cash flow above net income-$22.75M vs -$22.40M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.93 → 10.58
- No dilutionShare count did not rise35M → 57M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.81 → –